Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-powered risk adjustment, quality management, and HEDIS analytics for health plans and ACOs; raised $60M+. Glendale CA;
Reveleer is a health IT company that provides AI-powered solutions for risk adjustment, quality management, and care gap closure to health plans, ACOs, and provider organizations. Founded in 2014 and headquartered in Glendale, California, Reveleer has raised more than $60 million in growth capital. Its platform combines intelligent document ingestion, natural language processing, and workflow automation to help payers accurately capture risk and close quality gaps at scale, supporting programs like Medicare Advantage, Medicaid Managed Care, and ACA Marketplace.\n\nThe company's core capabilities include automated medical record retrieval, AI-assisted HCC coding review, HEDIS measure tracking, and clinical analytics that surface actionable insights across member populations. Reveleer's platform is designed to serve the full risk adjustment lifecycle from retrospective chart review through prospective care coordination, enabling health plans to improve risk accuracy while simultaneously identifying members who need targeted outreach for quality improvement.\n\nReveleer competes in a market increasingly defined by the financial importance of accurate risk scoring in value-based care contracts. The company has expanded its technology to include an integrated analytics layer that connects risk adjustment and quality data, helping health plans understand the intersection between clinical gaps and revenue impact. Its cloud-native architecture and configurable workflow engine make it adaptable to the specific program requirements of national and regional health plans.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.